ArticleOncoscience2026
Endometrial carcinosarcoma with multi-classifier molecular signature (MMRd-p53abn): A case report.
Article in Oncoscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The uterine carcinosarcoma is a rare biphasic Malignant Mixed Mullerian Tumour (MMMT). It is a highly aggressive endometrial cancer phenotype, consisting of both epithelial and mesenchymal components. The presented case refers to a 65-year-old, P6L3 postmenopausal woman with postmenopausal bleeding and white discharge per vagina for one month with vulval leukoplakia. The ultrasound showed a thickened endometrium measuring 15 mm, and the Magnetic Resonance Imaging showed the uterus measuring 7.4 × 4.5 × 6 cm. The endometrium appeared heterogeneous, with a hyperintense lesion measuring 4.8 × 2.3 cm on T2W1. The myometrium appeared normal, and neither of the ovaries was visualized. The patient underwent surgery. The histopathological and immunohistochemical analysis suggested that high-grade Endometrial Carcinosarcoma with dual classifier positivity (MMRd-p53abn) more closely resembled single-classifier MMRd (Mismatch repair deficiency) than p53abn, with a good prognosis. Post-surgery, the patient was followed up on every three months. The patient received 6 cycles of adjuvant chemotherapy. Considering the highly invasive nature of uterine carcinosarcomas, the timely detection of this cancer by imaging, pathology findings and molecular classification is of extreme importance to improve the patient's survival and for management outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.